专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20200046762A1 SMECTITE SUSPENSION LIQUID COMPOSITION AND METHOD FOR PREPARING SAME 审中-公开
公开(公告)号：US20200046762A1
公开(公告)日：2020-02-13
申请号：US16604173
申请日：2018-04-12
申请人： Daewoong Pharmaceutical Co., Ltd. , Liaoning Daewoong Pharmaceutical Co., Ltd.
发明人： Ye CHANG , Qing Ri LI , Sang Ho SEOL , Tie LI , Chao TONG
IPC分类号： A61K33/12 , A61K9/10 , A61K47/36 , A61K47/10 , A61K47/26 , A61K47/12
摘要： The present invention relates to a suspension comprising smectite, and the suspension of the present invention comprises both a polymeric suspending agent and a low molecular suspending agent, and thus exhibits high dispersibility and sinking rate, ease of administration due to not high viscosity of a formulation, enhanced drug compliance while taking the formulation, and high preference. In addition, the suspension of the present invention enables uniform dispersion in preparation thereof, thus exhibiting ease of preparation and excellent efficiency, and accordingly, has an excellent effect on reducing a defect rate in the production of a suspension preparation.

2. 发明授权

US11135165B2 Suspension comprising aluminum hydroxide and magnesium hydroxide and preparation method therefor 有权
公开(公告)号：US11135165B2
公开(公告)日：2021-10-05
申请号：US16604167
申请日：2018-04-12
申请人： Daewoong Pharmaceutical Co., Ltd. , Liaoning Daewoong Pharmaceutical Co., Ltd.
发明人： Ye Chang , Qing Ri Li , Sang Ho Seol , Tie Li , Chao Tong
IPC分类号： A61K9/10 , A61K33/08 , A61K47/34 , A61K47/36 , A61K47/38
摘要： The present invention provides a suspension comprising aluminum hydroxide and magnesium hydroxide and a method of preparing the same. The aqueous suspension composition according to the present invention ensures an excellent sedimentation rate by using a mixed suspending agent with a specific composition, so that insoluble aluminum hydroxide and magnesium hydroxide do not easily settle, do not form a cake, and are easily redispersed. Since the aqueous suspension composition having an excellent sedimentation rate has not only physical stability, but also forms a homogeneous dispersion system, the reproducibility or effectiveness of bioavailability may be ensured. In addition, the aqueous suspension composition according to the present invention provides an excellent texture, and thus patient compliance increases.

3. 发明申请

US20220387476A1 Liquid Pharmaceutical Composition of 1-(5-(2,4-difluorophenyl)-1-((3-fluorophenyl)sulfonyl)-4-methoxy-1H-pyrrol-3-yl)-N-methylmethanamine 有权
公开(公告)号：US20220387476A1
公开(公告)日：2022-12-08
申请号：US17774888
申请日：2020-12-18
申请人： Daewoong Pharmaceutical Co., Ltd.
发明人： Yeon Jin Jung , Gyoung Won Kim , Gwan Young Kim , Hye Jung Jang
IPC分类号： A61K31/724 , A61K47/26 , A61K31/341 , A61K9/00 , A61K9/16
摘要： The present invention can be usefully used as a liquid pharmaceutical composition of 1-(5-(2,4-difluorophenyl)-1-((3-fluorophenyl)sulfonyl)-4-methoxy-1H-pyrrol-3-yl)-N-methylmethanamine, or a pharmaceutically acceptable salt thereof.

4. 发明授权

US11345660B2 Method for preparing intermediate of 4-methoxypyrrole derivative 有权
公开(公告)号：US11345660B2
公开(公告)日：2022-05-31
申请号：US16608924
申请日：2018-06-21
申请人： Daewoong Pharmaceutical Co., Ltd.
发明人： Jeong-Taek Shin , Jeong-Hyun Son , Seung Chul Lee
IPC分类号： C07D207/36
摘要： The present invention relates to a method for preparing intermediates of 4-methoxypyrrole derivatives. The preparation method according to the present invention has advantages that the production cost can be lowered by using inexpensive starting materials, a high-temperature reaction is not required as a whole, inexpensive and non-explosive reagents are used instead of (trimethylsilyl)diazomethane, and further an intermediate of 4-methoxypyrrole derivatives can be prepared as a whole at a high yield.

5. 发明申请

US20220133720A1 PHARMACEUTICAL COMPOSITION OF SINGLE DOSAGE FORM FOR TREATING OR PREVENTING HYPERTENSION AND HYPERLIPIDEMIA 有权
公开(公告)号：US20220133720A1
公开(公告)日：2022-05-05
申请号：US17431464
申请日：2020-02-26
申请人： Daewoong Pharmaceutical Co., Ltd.
发明人： Ji Yeon KIM , Bo Hoon KIM
IPC分类号： A61K31/505 , A61K31/4178 , A61K31/4422 , A61K9/20 , A61K9/24 , A61K9/28
摘要： A pharmaceutical composition of a single dosage form for treating hypertension and hyperlipidemia is provided. Compartments containing a drug are formulated in separate forms to solve problems related to the dissolution and absorption of the drug due to drug interaction, and a biologically equivalent preparation can be obtained compared with a conventional single preparation.

6. 发明申请

US20220125889A1 COMPOSITION COMPRISING ALBUMIN-COUPLED SLIT3 LRRD2 FOR PREVENTION OR TREATMENT OF MUSCLE DISEASE 有权
公开(公告)号：US20220125889A1
公开(公告)日：2022-04-28
申请号：US17434388
申请日：2020-02-27
申请人： Daewoong Pharmaceutical Co., Ltd.
发明人： Jung Min KOH , Sung Sub KIM , Kyong Hoon AHN
IPC分类号： A61K38/38 , A61K47/64 , A61P21/00 , A61K9/00
摘要： The present invention relates to a composition comprising albumin-bound Slit3 LRRD2 for prevention or treatment of a muscle disease, and more particularly provides a fusion protein comprising albumin-bound Slit3 LRRD2, a nucleic acid molecule encoding the fusion protein, a recombinant vector comprising the nucleic acid molecule, a transformant comprising the recombinant vector, a method for preparing a fusion protein using the transformant, a composition comprising the fusion protein for prevention or treatment of a muscle disease, and a composition comprising the fusion protein for improving the in vivo half-life of LRRD2 of the Slit 3 protein.

7. 发明申请

US20220064155A1 NOVEL HETEROCYCLIC AMINE DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING SAME 有权
公开(公告)号：US20220064155A1
公开(公告)日：2022-03-03
申请号：US17269325
申请日：2019-08-27
申请人： Daewoong Pharmaceutical Co., Ltd.
发明人： Wol Young Kim , Yeon Im Lee , Youn Jung Yoon , Joon Seok Park , Deok Ki Eom , Keuk-Chan Bang , Jaehyun Jung
IPC分类号： C07D417/14 , C07D471/04 , C07D413/04
摘要： The present disclosure relates to a novel heterocyclic amine derivative represented by the following Chemical Formula 1 and a pharmaceutical composition comprising the same, and the compound according to the present disclosure can be usefully used for the prevention or treatment of autoimmune diseases or cancers. wherein, in Chemical Formula 1, R1, R2, X1, X2, L, Y, A and B are the same as defined in the specification.

8. 发明申请

US20210322272A1 TWO-CHAMBER TYPE COMBINED CONTAINER-SYRINGE 有权
公开(公告)号：US20210322272A1
公开(公告)日：2021-10-21
申请号：US17253667
申请日：2018-11-27
申请人： DAEWOONG PHARMACEUTICAL CO., LTD.
发明人： Duck Soo Lim , Jun Sik Kim , Tae Ho Lee , Sung Hoon Park
IPC分类号： A61J1/20
摘要： The present invention provides a two-chamber type combined container-syringe including: a cylinder having a first end portion, a second end portion in an opposite direction of the first end portion, and a bypass portion disposed between the first end portion and the second end portion; a finger grip mounted on the second end portion of the cylinder; a first stopper, a second stopper, and a third stopper that are sequentially disposed from the first end portion toward the second end portion in a space of the cylinder; and a plunger rod that is connected to the third stopper and has a plurality of support ribs provided to come in contact with an inner surface of the finger grip, wherein a space between the first stopper and the second stopper forms a front chamber, a space between the second stopper and the third stopper forms a rear chamber, a first ingredient and a second ingredient are accommodated in the front chamber and the rear chamber, respectively, a length ratio of the front chamber and the rear chamber is in a range of 1.6:1 to 3:1 when the plunger rod is at an initial position which is a state before the front chamber and the rear chamber communicate with each other through the bypass portion, and at the initial position, one or more support ribs are disposed in at least one of the finger grip and a region in the cylinder that is adjacent to the finger grip.

9. 发明申请

US20210292291A1 METHOD FOR PRODUCING INTERMEDIATE USEFUL FOR SYNTHESIS OF SGLT INHIBITOR 有权
公开(公告)号：US20210292291A1
公开(公告)日：2021-09-23
申请号：US17266844
申请日：2019-08-09
申请人： Daewoong Pharmaceutical Co., Ltd.
发明人： Qing Ri LI , Hee Kyoon YOON
IPC分类号： C07D307/79
摘要： A method of preparing an intermediate useful for the synthesis of a diphenylmethane derivative that can be used as an SGLT inhibitor is described. A method of synthesizing a compound of Formula 7 can address problems of existing synthesis processes requiring the synthesis of the Grignard reagent and management of related substances. In addition, the method can minimize the generation of related substances, and thus does not require reprocessing of reaction products, thereby simplifying the process. Accordingly, the production yield of a diphenylmethane derivative can be maximized.

10. 发明授权

US11116715B2 Composition for dermal injection 有权
公开(公告)号：US11116715B2
公开(公告)日：2021-09-14
申请号：US16489363
申请日：2018-02-27
申请人： CG Bio Co., Ltd. , DNCompany , Daewoong Pharmaceutical Co., Ltd.
发明人： Ji Sun Lee , Su Hyun Jung , Hak Su Jang , Jung Eun Choo , Hye Young Jung
IPC分类号： A61K8/73 , A61K8/64 , A61Q19/08
摘要： The present invention relates to a composition for dermal injection which includes two or more types of cross-linked hyaluronic acid particles having different particle diameters and non-cross-linked hyaluronic acid. The composition for dermal injection according to the present invention satisfies viscosity, extrusion force, and viscoelasticity conditions for dermal injection, and an extrusion force deviation is low so that the user does not feel fatigue when the composition is injected into the dermal thereof. Also, the composition is excellent in viscoelasticity and tissue restoring ability, is maintained for a long period of time, allows rapid recovery because an initial swelling degree is low, and also is excellent in safety and stability in the body.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式